Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

DOCS.NYSE

Doximity

Healthcare | Health Information Services

Doximity, Inc. operates as a digital platform for medical professionals in the United States.

Flagship Insight

Why This Hidden Digital Healthcare Leader Is Quietly Retiring Its Own Float

There is high consensus that this digital healthcare network operates as a highly defensible physician platform. While temporary regulatory headwinds compress near-term advertising budgets, the primary driver remains an aggressive, self-funded capital return program. The chief risk involves potential workflow disintermediation by native electronic health record systems.

Forecast TimelineUpdated On Jul 02 2026

Doximity (DOCS) Stock Forecast and AI Rating

Recommendation

No Action - Keep Monitoring

Only one horizon is positive; wait for broader confirmation.

2027

1-Year

BUY

$26

+19.3%

+21% IF INCL. DIVS

2029

3-Year

N/A

$34

+60%

2031

5-Year

NEUTRAL

$42

+91%

+98% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset is undergoing a structural transition from a hyper-growth software narrative to an elite, cash-generative digital utility. Despite near-term top-line deceleration driven by regulatory freezes in pharmaceutical marketing budgets, the core business model remains highly defensible. The company commands authenticated network access to over eighty percent of practicing domestic physicians, establishing an entrenched workflow moat. Operating with zero debt and near-ninety percent gross margins, the platform generates exceptional free cash flow, which management is aggressively deploying to retire outstanding equity. This self-funded capital return program provides a robust valuation floor and mathematically compounds per-share earnings power, insulating the asset from macroeconomic and interest rate shocks.

Key insights

The highly defensible physician network effect secures long-term pricing power over pharmaceutical advertisers.
Aggressive open-market share repurchases systematically shrink the float, driving structural per-share value accretion.
Strategic R&D investments in agentic clinical AI tools defend the workflow interface against emerging competitors.
Regulatory price controls on pharmaceuticals present a persistent headwind to aggregate marketing budgets.
The primary structural risk stems from potential native workflow integration by dominant electronic health record providers.
Sophisticated investors should accumulate during this margin trough, capitalizing on the disconnect between optical GAAP deceleration and underlying cash-flow durability.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Doximity quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Doximity.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$20.55	$22.59	$23.61	$736.09
Quarter 2+6M	Jan 02, 2027	$19.73	$23.28	$25.03	$724.14
Quarter 3+9M	Apr 02, 2027	$18.74	$24.37	$27.50	$713.57
Quarter 4+1Y	Jul 02, 2027	$19.11	$25.47	$28.90	$723.38
Quarter 5+15M	Oct 02, 2027	$18.16	$26.09	$30.06	$716.61
Quarter 6+18M	Jan 02, 2028	$17.07	$27.03	$32.19	$738.34
Quarter 7+21M	Apr 02, 2028	$16.39	$28.06	$33.80	$746.91
Quarter 8+2Y	Jul 02, 2028	$16.88	$28.99	$34.46	$771.93
Quarter 9+27M	Oct 02, 2028	$16.37	$29.48	$35.84	$782.73
Quarter 10+30M	Jan 02, 2029	$16.04	$30.53	$38.35	$807.31
Quarter 11+33M	Apr 02, 2029	$15.56	$31.92	$39.50	$822.72
Quarter 12+3Y	Jul 02, 2029	$15.72	$33.10	$42.66	$846.10
Quarter 13+39M	Oct 02, 2029	$15.09	$33.87	$41.38	$852.53
Quarter 14+42M	Jan 02, 2030	$14.79	$35.07	$43.45	$882.91
Quarter 15+45M	Apr 02, 2030	$14.34	$36.40	$46.16	$900.46
Quarter 16+4Y	Jul 02, 2030	$14.63	$37.03	$46.54	$922.67
Quarter 17+51M	Oct 02, 2030	$14.05	$37.80	$46.32	$935.91
Quarter 18+54M	Jan 02, 2031	$13.77	$38.74	$48.64	$952.30
Quarter 19+57M	Apr 02, 2031	$13.35	$40.26	$51.78	$976.28
Quarter 20+5Y	Jul 02, 2031	$13.09	$41.70	$53.85	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's mischaracterization of the company's business model and capital allocation strategy. While the crowd sells the stock due to slowing revenue growth and optical margin compression, they fail to recognize the durability of its cash conversion. The company operates a highly defensible network on physician attention, boasting near-ninety percent gross margins and a forty-nine percent free cash flow margin. The elevated research and development spending is not desperate flailing, but a calculated, self-funded moat-building exercise to lock in physicians with free clinical artificial intelligence tools. Most critically, the market ignores the mathematics of a ten percent net buyback yield. By aggressively retiring the float at a depressed multiple, management is engineering massive per-share earnings compounding that does not rely on top-line hyper-growth.

Advisor Disagreement

The primary disagreement across the reports centers on the long-term viability of the company's artificial intelligence transition. Optimistic views assume that the elevated research and development spending is a highly productive, temporary investment that will successfully secure the physician workflow and unlock lucrative enterprise SaaS revenues. Conversely, skeptical perspectives argue that the spending represents a defensive, margin-diluting catch-up effort that faces structural obsolescence against native electronic health record systems and frontier models. There is also minor divergence regarding the near-term trajectory of pharmaceutical advertising budgets, with some expecting a rapid post-regulatory normalization and others projecting a prolonged structural contraction.

Financial Reviews by iPulse AI

Earnings and financials

The company is currently experiencing a tale of two financial statements. On one hand, sales growth has slowed down significantly from its pandemic-era highs, and net income has dropped due to a big jump in spending on artificial intelligence technology. On the other hand, the company's cash generation remains absolutely spectacular, bringing in a record amount of free cash flow that represents nearly half of its total revenue. The reports strongly agree that this cash-flow engine is incredibly healthy and provides a solid safety net. However, there is a clear disagreement on the future outlook: some believe that sales will quickly bounce back as drug companies return to the platform, while others worry that the slowdown is permanent and that high technology costs will continue to eat into profits. Overall, the massive cash flow is being used to buy back shares, which helps protect investors.

Profitability and margins

The company's core profitability remains exceptionally strong, highlighted by gross margins near ninety percent, meaning it costs almost nothing to serve each additional user on the platform. However, operating margins have recently shrunk because the company is spending heavily on artificial intelligence and computer power. The reports agree that this margin squeeze is happening, but they clash on what comes next. Some believe this is a temporary dip and that profit margins will bounce back once the new AI tools are fully built and start making money. Others argue that running advanced AI tools is structurally more expensive than running a simple social network, meaning profit margins may never return to their historical highs. Despite this squeeze, the company remains far more profitable than the average business, making its current valuation look highly attractive to cash-focused investors.

Balance sheet and leverage

The company's balance sheet is an absolute fortress, and there is unanimous agreement across all reports on its incredible safety. The company carries virtually zero debt and holds a massive pile of cash and short-term investments. This means the company faces no risk of running out of money or struggling with high interest rates, which are currently hurting many other tech firms. This financial safety gives management the unique ability to act aggressively while others are playing defense. Specifically, they are using their cash to buy back a massive amount of their own stock, which makes each remaining share more valuable. There is very little disagreement here; the balance sheet completely protects the company from bad economic times and gives it the flexibility to buy up struggling competitors or continue returning cash to its shareholders.

Capex and investment intensity

The company operates an incredibly light business model that requires almost no spending on physical equipment or buildings, which is a huge advantage when costs are rising elsewhere. Instead, the company is focusing its financial power on research and development to build advanced artificial intelligence tools for doctors. The reports agree that this heavy spending is a deliberate move to protect the company's network from competitors. However, opinions differ on what this spending means for the future. Optimistic views see this as a smart, long-term investment that will eventually allow the company to charge hospitals recurring software fees. Skeptical views worry that this is a costly, defensive move that might not bring in new revenue, especially since giant tech companies are spending billions on similar tools. Investors should watch whether these new tools actually help the company grow.